The exploratory approach ensuring higher sensitivity was deemed the most relevant when exploring ANA in non-connective tissue diseases, excluding more specific solid phase assays as no specific autoantibodies have been associated with synucleinopathies. The gene discussed is BTG3; the disease is connective tissue disorder.